Beginner's Mind
Alasdair Milton, KPMG | Why Precision Medicine Still Fails Patients (SPARK20 – 168)
24:51
Only one in three eligible lung cancer patients receives the targeted therapy they should get.
That is not a failure of science.
It is a failure of delivery.
After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.
Yet too…